1. Home
  2. ASIC vs ABCL Comparison

ASIC vs ABCL Comparison

Compare ASIC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASIC

Ategrity Specialty Insurance Company Holdings

N/A

Current Price

$21.43

Market Cap

1.0B

Sector

Finance

ML Signal

N/A

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$3.60

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASIC
ABCL
Founded
2018
2012
Country
United States
Canada
Employees
N/A
596
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
ASIC
ABCL
Price
$21.43
$3.60
Analyst Decision
Strong Buy
Buy
Analyst Count
4
5
Target Price
$25.50
$7.75
AVG Volume (30 Days)
95.4K
3.1M
Earning Date
10-22-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
504.00
N/A
EPS
0.17
N/A
Revenue
$405,657,000.00
$35,325,000.00
Revenue This Year
$14.87
$25.45
Revenue Next Year
$44.91
$10.07
P/E Ratio
$123.86
N/A
Revenue Growth
68.10
7.17
52 Week Low
$16.35
$1.89
52 Week High
$25.30
$6.52

Technical Indicators

Market Signals
Indicator
ASIC
ABCL
Relative Strength Index (RSI) N/A 44.29
Support Level N/A $3.32
Resistance Level N/A $3.82
Average True Range (ATR) 0.00 0.19
MACD 0.00 0.06
Stochastic Oscillator 0.00 51.85

Price Performance

Historical Comparison
ASIC
ABCL

About ASIC Ategrity Specialty Insurance Company Holdings

Ategrity Specialty Insurance Co Holdings Formerly Ategrity Specialty Holdings LLC is a specialty insurance company dedicated to providing excess and surplus products to small to medium-sized businesses across the United States. It offers property and casualty insurance solutions tailored to meet the needs of SMBs. The company focuses on are Real Estate, Hospitality, Construction, and Retail.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: